Cardiac Resynchronization Therapy for Congestive Heart Failure: Evidence Report/Technology Assessment Number 106 - Couverture souple

Human Services, U.S. Department Of Health And; And Quality, Agency For Healthcare Research

 
9781499671995: Cardiac Resynchronization Therapy for Congestive Heart Failure: Evidence Report/Technology Assessment Number 106
Couverture souple
ISBN 10 : 1499671997 ISBN 13 : 9781499671995
Editeur : CreateSpace Independent Publishing Platform, 2014

Synopsis

Heart failure is the fastest growing cardiovascular diagnosis in North America, and it carries a poor prognosis. To improve survival in heart failure patients, therapies need to reduce either sudden cardiac death (the most common cause of death in patients with New York Heart Association [NYHA] Class I or II symptoms) or progressive heart failure (the predominant cause of death in those with NYHA Class III or IV symptoms). Electrical conduction disturbances are common in heart failure and are associated with increased mortality risk. Atrial-synchronized biventricular pacing (cardiac resynchronization therapy [CRT]) addresses many of the pathophysiological changes seen in patients with wide QRS complexes in whom delayed activation of the left free wall results in mechanical dyssynchrony. The University of Alberta Evidence-based Practice Center conducted a systematic review to examine the success rate and safety of biventricular pacemaker implantation and the efficacy of CRT in patients with heart failure. Further, the researchers used these data in a decision analysis to evaluate the incremental cost effectiveness of CRT versus medical therapy alone. This report addresses the following questions: 1. In adult patients with symptomatic heart failure, is CRT more effective than optimal medical care alone? 2. Is the implantation of a CRT system safe for patients? 3. What is the role of CRT in the treatment of heart failure? 4. What is the cost-effectiveness of CRT in patients with congestive heart failure?

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

Heart failure is the fastest growing cardiovascular diagnosis in North America, and it carries a poor prognosis. To improve survival in heart failure patients, therapies need to reduce either sudden cardiac death (the most common cause of death in patients with New York Heart Association [NYHA] Class I or II symptoms) or progressive heart failure (the predominant cause of death in those with NYHA Class III or IV symptoms). Electrical conduction disturbances are common in heart failure and are associated with increased mortality risk. Atrial-synchronized biventricular pacing (cardiac resynchronization therapy [CRT]) addresses many of the pathophysiological changes seen in patients with wide QRS complexes in whom delayed activation of the left free wall results in mechanical dyssynchrony. The University of Alberta Evidence-based Practice Center conducted a systematic review to examine the success rate and safety of biventricular pacemaker implantation and the efficacy of CRT in patients with heart failure. Further, the researchers used these data in a decision analysis to evaluate the incremental cost effectiveness of CRT versus medical therapy alone. This report addresses the following questions: 1. In adult patients with symptomatic heart failure, is CRT more effective than optimal medical care alone? 2. Is the implantation of a CRT system safe for patients? 3. What is the role of CRT in the treatment of heart failure? 4. What is the cost-effectiveness of CRT in patients with congestive heart failure?

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
CreateSpace Independent Publishing Platform
Date d'édition
2014
Langue
anglais
ISBN 10 
1499671997
ISBN 13 
9781499671995
Reliure
Broché
Nombre de pages
174
Coordonnées du fabricant
Manufactured by Amazon on behalf of the author
https://www.amazon.fr/hz/contact-us

c/o Amazon Media EU S.à.r.l., 38 Avenue John F. Kennedy
Luxembourg
L-1855
Luxembourg